Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation
摘要： Measurable residual disease(MRD) has become a critical biomarker in the management of acute lymphoblastic leukemia(ALL), particularly for patients undergoing allogeneic hematopoietic stem ce... ...
（共19页）
开通会员，享受整站包年服务
说明： 本文档由创作者上传发布，版权归属创作者。若内容存在侵权，请点击申诉举报
APP